Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/28/2025 | $8.00 | Buy → Hold | Stifel |
| 12/4/2024 | Outperform | William Blair | |
| 12/19/2023 | $13.00 → $4.00 | Equal-Weight → Underweight | Morgan Stanley |
| 10/18/2023 | $23.00 | Mkt Outperform | JMP Securities |
| 3/31/2023 | $15.00 | Buy | Mizuho |
| 9/16/2022 | $19.00 | Outperform | Wedbush |
| 8/29/2022 | $24.00 | Buy | H.C. Wainwright |
| 2/1/2022 | $17.00 | Equal-Weight | Morgan Stanley |
4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)
4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)
4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)
PREM14A - Vigil Neuroscience, Inc. (0001827087) (Filer)
SCHEDULE 13G - Vigil Neuroscience, Inc. (0001827087) (Subject)
SCHEDULE 13G - Vigil Neuroscience, Inc. (0001827087) (Subject)
WATERTOWN, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced an update on the Phase 2 IGNITE open-label clinical trial evaluating iluzanebart, a monoclonal antibody TREM2 agonist, for the potential treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP). Iluzanebart demonstrated a favorable safety, tolerability and pharmacokinetic profile across both the 20 mg/kg and 40 mg/kg dose cohorts. The Phase 2 IGNITE trial showed no beneficial effects on biomarker or clinical effica
- Vigil's shareholders to receive up to $10.00 per share in cash, comprised of $8.00 per share in cash at closing and a non-tradeable contingent value right of $2.00 per share in cash following the first commercial sale of VG-3927 - - Acquisition expected to strengthen development path for the oral small molecule TREM2 agonist program, including VG-3927, a Phase 2-ready clinical candidate for potential treatment of Alzheimer's disease – - Companies expect transaction to close in third quarter of 2025 - WATERTOWN, Mass., May 21, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for
– On track to report final analysis from IGNITE Phase 2 clinical trial evaluating iluzanebart in ALSP in Q2 2025 – – Plans to initiate Phase 2 clinical trial evaluating VG-3927 in Alzheimer's disease in Q3 2025 – WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the first quarter ending March 31, 2025, and provided updates on its recent progress. "During the quarter, we continued to make meaningful progress across our two TREM2 programs, VG-3927 and iluzanebart," said Ivana Ma